Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19 CAR-T and CAR-DC in Relapsed/Refractory B-cell Lymphoma
NCT05585996Phase 1Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Aug 2022
- Primary completion
- Nov 2025
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Autologous CD19 CAR-T (Institute of Hematology & Blood Diseases Hospital) in B cell lymphoma, sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoints: Dose-Limiting Toxicity at 28 days, Maximum Tolerated Dose at 28 days and 1 more. Started Aug 2022; status: recruiting.
02
Drugs
Autologous CD19 CAR-T (Institute of Hematology & Blood Diseases Hospital)
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT05585996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05585996.